Form 4: Ginkgo Bioworks Executive Steven P. Coen Reports Stock Transactions

Steven P. Coen, Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc., reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• On May 20, 2025, Steven P. Coen, Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc., had restricted stock units (RSUs) vest, resulting in the acquisition of 587 and 156 shares of Class A Common Stock.
• Following these transactions, Coen directly owns 9,406 and 9,562 shares of Class A Common Stock respectively.
• On May 21, 2025, Coen sold 346 shares at a price of $7.585 per share to cover tax withholding obligations related to the vesting of the RSUs, leaving a balance of 9,216 shares.
• The RSUs vest in monthly installments following an initial vesting date of May 1, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• Similar filings are made by executives at companies like Amyris and Zymergen (now Ginkgo Bioworks), disclosing stock transactions.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
• The filing provides transparency to shareholders regarding insider trading activities.

Key Dates

Keywords

Ginkgo Bioworks, DNA, Form 4, SEC Filing, Insider Trading, Steven P. Coen, Restricted Stock Units, Class A Common Stock, Tax Withholding